Oral / Subcutaneous · GLP-1 / GIP dual
BGM0504
15 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
15
Active
10
Recruiting
9
Completed
5
Sites
10
Countries
3
Endpoints
91
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
7
Phase 2
4
Phase 3
4
Trials by status
Not yet recruiting
1
Recruiting
9
Completed
5
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
32
Weight & body composition
29
Glycemic / diabetes
25
Cardiometabolic biomarkers
3
Patient-reported / QoL
1
Other clinical outcomes
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Body weight, absolute change (kg)Weight
10
HbA1c, changeGlycemic
8
Fasting glucose, changeGlycemic
7
Treatment-emergent AEs (any)Safety/PK
6
CmaxSafety/PK
6
AUC₀–∞Safety/PK
5
HbA1c <7.0% achievementGlycemic
4
HbA1c <5.7% achievementGlycemic
4
Waist circumference, changeWeight
4
Plasma concentration (steady state)Safety/PK
3
Half-lifeSafety/PK
3
Body weight, % changeWeight
3
≥5% weight-loss respondersWeight
3
BMI, changeWeight
3
TmaxSafety/PK
2
Serious AEs (any)Safety/PK
1
≥10% weight-loss respondersWeight
1
≥15% weight-loss respondersWeight
1
≥20% weight-loss respondersWeight
1
Systolic BP, changeBiomarker
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
15 of 15